NRXP Expands Access Protocol
NRx Pharmaceuticals announces FDA grant of expanded access protocol for use of D-Cycloserine-based NRX-101 for augmentation of transcranial magnetic stimulation in the treatment of depression
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.